Needham Reiterates Buy on AtriCure, Maintains $60 Price Target
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Mike Matson reiterates a Buy rating on AtriCure (NASDAQ:ATRC) and maintains a $60 price target.
June 02, 2023 | 9:15 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Mike Matson reiterates a Buy rating on AtriCure and maintains a $60 price target.
The reiteration of a Buy rating by Needham analyst Mike Matson indicates a positive outlook for AtriCure's stock. The maintained $60 price target suggests that the analyst believes the stock has potential for growth in the short term. This news is likely to have a positive impact on ATRC's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100